Archbishop Michael Jude Byrnes, 64, has been on “extended medical leave” off island, Archdiocesan Vicar General Father Romeo Convocar said on Tuesday. But the archdiocese did not provide ...

Founder, president and chief executive officer of American Quality Schools Dr. Michael J. Bakalis is founder, President and Chief Executive Officer of American Quality Schools. He also served on the ...

Widely respected Catholic theologian Rev. Michael J. Himes, a beloved faculty member at Boston College for almost three decades, died on June 10 at the age of 75.

Whitemarsh Township held a special meeting Thursday night to discuss the cancelation of this year's July 4th parade, which was called off because of public safety concerns. Residents said the ...

St. Michael the Archangel, defend us in battle. Be our defense against the wickedness and snares of the Devil. May God rebuke him, we humbly pray, and do thou, O Prince of the heavenly hosts, by ...

Hicks came to Ball State following stints at the Air Force Institute of Technology’s Graduate School of Engineering and Management and research centers at Marshall University and the University of ...

Michael J. Driscoll, who most recently headed the FBI’s Philadelphia Field Office, has been named assistant director of the New York Field Office. Driscoll is no stranger to the New York Field Office, ...

The two passengers killed in a single-vehicle crash early Sunday on the New Jersey Turnpike in Gloucester County are both teenagers from Maryland, officials said. Juan Carlos Munguia-Palma, 19 ...

Michael Copley is a correspondent on NPR's Climate Desk. He covers what corporations are and are not doing in response to climate change, and how they're being impacted by rising temperatures.

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra (fo ...

Just two quarterbacks were taken in the first round of the NFL Draft, and while it's likely both of them will start this season, history has proven that fantasy football rookies can't necessarily ...

Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics in an all-cash deal valued at $1.25 billion. Under the terms of the ...